PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ijnlThis JournalSearchAuthor GuidelinesAim and ScopeSubmit a ManuscriptIranian Journal of Neurology
 
Iran J Neurol. 2016 April 3; 15(2): 109–110.
PMCID: PMC4912669

Influenza vaccination in patients with multiple sclerosis is possible with some considerations

Introduction

Influenza is a disease of particular concern for patients with multiple sclerosis (MS). Is influenza vaccine good for MS?

Types of influenza vaccine

Two types of influenza vaccine are used. The first one includes inactivated (killed) influenza virus administered intramuscularly and the second, live, attenuated, virus administered intranasally via an aerosol sprayer.1 Live attenuated vaccine is not recommended for MS patients.

Risk of MS onsets after influenza vaccination

Studies of the onset of MS after influenza vaccination had very serious methodological limitation and did not report any association between influenza vaccination and the increased risk of MS in adults.2-5

Influenza disease in patients with MS

Two studies showed that the risk of influenza-related hospitalizations, mortality, morbidity and relapse increased in patients with relapsing-remitting MS (RRMS).6,7

Influenza vaccination and relapse

It seems that influenza vaccination has a protective effect on MS and does not seem to exacerbate or deteriorate neurological status.7,8 Nevertheless, there is a small case series reporting relapses within 3 weeks of simultaneous H1N1 and seasonal vaccination.9

MS drugs and influenza vaccination

Corticosteroid: Corticosteroids did not prove to impair the immune response following influenza vaccination.10

Interferon-beta (INF-β): Seasonal influenza vaccination is safe and effective in 90.9% and 93.0% INF-treated patients.11

Glatiramer acetate (GA): GA ‎may present a lower protection after influenza vaccination compared to healthy individuals.12

Mitoxantrone: Mitoxantrone can impair influenza vaccine immunogenicity and efficacy.12

Teriflunomide: The TERIVA study showed that influenza vaccination was sufficient in providing the considered protection in patients treated with teriflunomide.13

Dimethyl fumarate: There is not any data on dimethyl fumarate and influenza vaccination.

Fingolimod: Influenza vaccination in fingolimod-treated patients could be safe and protective but need a booster dose.14

Natalizumab: Influenza vaccination could be safe and protective in natalizumab-treated patients.15

Cytotoxic: Azathioprine-treated patients with systemic lupus erythematosus (SLE) had a diminished antibody response following influenza vaccination.16

Intravenous immunoglobulin (IVIG): The immunogenicity of live vaccines was impaired by IVIG for 6-12 months.17

Rituximab: In rituximab-treated patients, vaccination with inactivated vaccines might be effective.18

Time of vaccination

Following corticosteroid pulse therapy, it is recommended to delay vaccination for at least 2 weeks. In patients with MS treated with mitoxantrone and cyclophosphamide, it should be done between drug cycles. In immunosuppressive therapy, antibody testing is recommended 4 weeks following the vaccination and if the antibody titers failed to rise, revaccination should be kept in mind.19

Acknowledgments

None.

Conflict of Interests

The authors declare no conflict of interest in this study.

Notes:

How to cite this article: Baghbanian SM. Influenza vaccination in patients with multiple sclerosis is possible with some considerations. Iran J Neurol 2016; 15(2): 109-10.

References

1. TreanorJJ . Influenza viruses, including avian influenza and swine influenza. In: Mandell G, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. London, UK: Churchill Livingstone/ Elsevier; 2010. pp. 2265–88.
2. Lauer K, Firnhaber W. The possible risk of vaccinations for the first manifestation of multiple sclerosis. Aktuelle Neurologie. 1990;17(2):42–6.
3. Ramagopalan SV, Valdar W, Dyment DA, de Luca GC, Yee IM, Giovannoni G, et al. Association of infectious mononucleosis with multiple sclerosis A population-based study. Neuroepidemiology. 2009;32(4):257–62. [PubMed]
4. de Stefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60(4):504–9. [PubMed]
5. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63(5):838–42. [PubMed]
6. Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol. 2013;20(8):1153–60. [PubMed]
7. Farez MF, Ysrraelit MC, Fiol M, Correale J. H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Mult Scler. 2012;18(2):254–6. [PubMed]
8. Auriel E, Gadoth A, Regev K, Karni A. Seasonal and H1N1v influenza vaccines in MS: safety and compliance. J Neurol Sci. 2012;314(1-2):102–3. [PubMed]
9. McNicholas N, Chataway J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol. 2011;258(8):1545–7. [PubMed]
10. Briggs WA, Rozek RJ, Migdal SD, Shillis JL, Brackett RG, Brandon FB, et al. Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses. Ann Intern Med. 1980;92(4):471–7. [PubMed]
11. Schwid SR, Decker MD, Lopez-Bresnahan M. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology. 2005;65(12):1964–6. [PubMed]
12. Olberg HK, Cox RJ, Nostbakken JK, Aarseth JH, Vedeler CA, Myhr KM. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Mult Scler. 2014;20(8):1074–80. [PubMed]
13. Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013;81(6):552–8. [PMC free article] [PubMed]
14. Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, et al. Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Neurology. 2015;84(9):872–9. [PubMed]
15. Vagberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. Neurol Res. 2012;34(7):730–3. [PubMed]
16. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002;29(12):2555–7. [PubMed]
17. Food and Drug Administration. Gammagard liquid- U.S. Food and Drug Administration [Online] [[cited 2012]]. Available from: URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm070010.pdf.
18. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81. [PubMed]
19. Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol. 2011;8(3):143–51. [PubMed]

Articles from Iranian Journal of Neurology are provided here courtesy of Tehran University of Medical Sciences